Immunic Q1 EPS $(0.30) Misses $(0.26) Estimate, Cash And Equivalents As Of March 31, 2024 Were $97.3M
Portfolio Pulse from Benzinga Newsdesk
Immunic (NASDAQ:IMUX) reported Q1 EPS of $(0.30), missing the $(0.26) estimate, marking a 15.38% miss but a 48.28% improvement over last year's $(0.58) per share loss. Cash and equivalents stood at $97.3M as of March 31, 2024.
May 08, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Immunic reported a Q1 EPS loss of $(0.30), missing estimates by 15.38%, but improved from last year's $(0.58) loss. Cash stands at $97.3M.
Missing the EPS estimate could negatively impact investor sentiment in the short term, despite the year-over-year improvement in losses and a solid cash position. The miss suggests potential operational or market challenges.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100